Nanobiotix S.A. (0QAV.L)
LSE · EUR
€29.90 (+6.41%) as of
Key statistics
- EPS (TTM)
- -1.36
- 52-week range
- 1.62 – 30.68
- Beta
- 0.59
- Revenue (TTM)
- 11.51M
- Profit margin
- 0.00%
- Volume
- 52.48k
About Nanobiotix S.A.
Nanobiotix S.A. operates as a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck, liver, prostate, pancreatic, esophageal, rectal, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is based in Paris, France.
- Headquarters
- Paris, France
- Employees
- 98
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.